Copyright
©The Author(s) 2025.
World J Gastrointest Surg. May 27, 2025; 17(5): 101605
Published online May 27, 2025. doi: 10.4240/wjgs.v17.i5.101605
Published online May 27, 2025. doi: 10.4240/wjgs.v17.i5.101605
Table 3 Comparative analysis of immunological biomarker responses between the two groups, mean ± SD
Experimental group (n = 45) | Control group (n = 44) | F value | P value | |
CD3+, % | 43.869 | < 0.001 | ||
Before treatment | 54.09 ± 5.33 | 53.93 ± 5.21 | 0.011 | 0.918 |
3 months after treatment | 69.18 ± 7.03 | 59.46 ± 6.72 | ||
CD4+, % | 39.005 | < 0.001 | ||
Before treatment | 32.64 ± 3.84 | 33.03 ± 3.79 | 1.223 | 0.272 |
3 months after treatment | 45.18 ± 4.91 | 39.06 ± 4.23 | ||
CD8+, % | 84.859 | < 0.001 | ||
Before treatment | 30.55 ± 4.52 | 31.13 ± 4.78 | 0.158 | 0.692 |
3 months after treatment | 21.76 ± 2.15 | 26.35 ± 2.52 | ||
CD4+/CD8+ | 103.782 | < 0.001 | ||
Before treatment | 1.10 ± 0.24 | 1.09 ± 0.22 | 0.643 | 0.425 |
3 months after treatment | 2.10 ± 0.33 | 1.50 ± 0.22 |
- Citation: Song T, Wu KH, Yang H, Xie WL, Shen L. Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma. World J Gastrointest Surg 2025; 17(5): 101605
- URL: https://www.wjgnet.com/1948-9366/full/v17/i5/101605.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i5.101605